Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 47 to 55 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Restore CFTR FunctionClosed to enrollment Location: Toronto
A phase 3 rollover study of VX-659 triple combination drug in people 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation (VX-659-105) , protocol number VX-659-105 NCT03447262
CFTR function study evaluating the long term safety and efficacy of VX-659 combination therapy
Age:
12+
Mutation(s):
One copy F508del
FEV1% Predicted:
Not specified
Number of Visits:
Length of Participation:
96 weeks
Restore CFTR FunctionClosed to enrollment Location: Vancouver, Montreal, Toronto
A phase 3 study of tazacaftor (VX-661) combination drug in children aged 6 years and older (VX17-661-116) , protocol number VX17-661-116) NCT03537651
CFTR function study, evaluating the safety and efficacy of long-term treatment with tezacaftor in combination with ivacaftor in subjects aged 6-11 years
6+
A phase 3 rollover study of VX-445 triple combination drug in people 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation (VX17-445-105) , protocol number VX17-445-105 NCT03525574
CFTR function study, evaluating the long-term effectiveness, safety, and effect on the body of the drug VX-445 in combination with tezacaftor and ivacaftor
Restore CFTR FunctionEnrolling Location: Toronto
A phase 3 open-label extension study in people 12 years and older (VX-18-445-113) , protocol number VX 18-445-113 NCT04043806
This study will evaluate the long term safety and tolerability of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA).
100 weeks
Restore CFTR FunctionClosed to enrollment Location: Montreal, Toronto and Vancouver
A phase 3 rollover study evaluating the long-term safety and efficacy of VX-445 triple combination therapy (VX18-445-110) , protocol number VX-445-100 NCT04058366
This study will evaluate the long-term safety, efficacy and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with texacaftor (TEX) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes).
Restore CFTR FunctionClosed to enrollment Location: Vancouver & Toronto
A phase 3 rollover study evaluating the long-term safety and efficacy of VX-445 combination therapy in subjects with cystic fibrosis who are 6 years of age and older (VX 18-445-107) , protocol number VX 18-445-107 NCT04183790
This study will evaluate the long-term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF).
Anti-InfectiveEnrolling Location: ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM)
ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM) , protocol number NCT04294043 NCT04294043
This study is taking place at multiple care centres across the U.S. It will look at the safety and tolerability IV gallium, a drug intended to treat infections in the lung.
18 Years and Older
No Mutation Requirement
25% of greater
8
20 weeks
Anti-InflammatoryEnrolling Location: Pennsylvania, USA
Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (CX-280-202) , protocol number CX-280-202 NCT04279769
This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.
40 to 90%
6
2 months
Restore CFTR FunctionEnrolling Location: Multiples sites across the United States
Study of ELX-02 in adults with cystic fibrosis who have at least one G542X mutation , protocol number ELX-02 Eloxx-EL-012
This study will look at the safety and tolerability of ELX-02 and how the body processes the drug, a molecule intended to restore CFTR function. Multiple doses of ELX-02 will be tested in adults with cystic fibrosis who have at least one G542X mutation.
No Copies F508del
40% or greater
15
15 weeks
Anti-InflammatoryRecruiting Location: Multiple centres across the US & Australia
Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD) , protocol number Laurent LAU-14-01 NCT03265288
An international Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF.
No Mutation Required
between 40% and 100%
189 days